Press coverage about Synergy Pharmaceuticals (NASDAQ:SGYP) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Synergy Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.7808274133779 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several brokerages have commented on SGYP. BTIG Research reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Synergy Pharmaceuticals in a research report on Tuesday, June 27th. BidaskClub raised Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Zacks Investment Research raised Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Monday, July 10th. Finally, Citigroup Inc. reaffirmed a “sell” rating and issued a $3.70 price objective on shares of Synergy Pharmaceuticals in a research report on Wednesday, June 28th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $9.32.

Synergy Pharmaceuticals (NASDAQ SGYP) traded down 1.89% during trading on Friday, hitting $2.59. The stock had a trading volume of 5,167,881 shares. Synergy Pharmaceuticals has a one year low of $2.57 and a one year high of $7.15. The firm has a 50 day moving average of $3.07 and a 200-day moving average of $4.01. The company’s market cap is $582.63 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.08). The business had revenue of $2.31 million during the quarter, compared to the consensus estimate of $1.98 million. During the same quarter in the prior year, the company earned ($0.23) EPS. Equities analysts anticipate that Synergy Pharmaceuticals will post ($1.14) earnings per share for the current fiscal year.

In other news, major shareholder Paulson & Co. Inc. sold 26,287 shares of Synergy Pharmaceuticals stock in a transaction on Monday, August 7th. The stock was sold at an average price of $3.77, for a total value of $99,101.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.80% of the stock is owned by insiders.

WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/24/synergy-pharmaceuticals-sgyp-receiving-somewhat-positive-media-coverage-study-shows.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Insider Buying and Selling by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Stock Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.